NICE Gives Soft ‘No’ to Janssen’s Leukemia Treatment, Rejects Roche’s Perjeta
The UK’s National Institute for Health and Care Excellence refused to recommend Janssen’s chronic lymphocytic leukemia treatment Imbruvica for reimbursement in June, but left the door open to further discussion.
Source: International Pharmaceutical Regulatory Monitor